Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe NIH website-transition announcement banner no longer appears above the 403 error page.SummaryDifference1%

- Check17 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.2 to v3.8.0, while the page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide banner announces NIH website transition updates and says federal agencies are shifting terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check31 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check45 days agoChange DetectedThe study record page displays a 403 Forbidden message and a Home link instead of the record content.SummaryDifference0.5%

Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.